1Nemours Children's Hospital, Thomas Jefferson University, Wilmington, Delaware.
2Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
J Neurosurg Pediatr. 2023 Sep 15;32(6):649-656. doi: 10.3171/2023.7.PEDS2354. Print 2023 Dec 1.
The objective of this study was to describe the incidence and management of hydrocephalus in patients with achondroplasia over a 60-year period at four skeletal dysplasia centers.
The Achondroplasia Natural History Study (CLARITY) is a registry for clinical data from achondroplasia patients receiving treatment at four skeletal dysplasia centers in the US from 1957 to 2017. Data were entered and stored in a REDCap database and included surgeries with indications and complications, medical diagnoses, and radiographic information.
A total of 1374 patients with achondroplasia were included in this study. Of these, 123 (9%) patients underwent treatment of hydrocephalus at a median age of 14.4 months. There was considerable variation in the percentage of patients treated for hydrocephalus by center and decade of birth, ranging from 0% to 28%, although in the most recent decade, all centers treated less than 6% of their patients, with an average of 2.9% across all centers. Undergoing a cervicomedullary decompression (CMD) was a strong predictor for treatment of hydrocephalus (OR 5.8, 95% CI 3.9-8.4), although that association has disappeared in those born since 2010 (OR 1.1, 95% CI 0.2-5.7). In patients born since 1990, treatment of hydrocephalus with endoscopic third ventriculostomy (ETV) has become more common; it was used as the first line of treatment in 38% of patients in the most recent decade. Kaplan-Meier analysis suggests that a single ETV will treat hydrocephalus in roughly half of these patients.
While many children with achondroplasia have features of hydrocephalus with enlarged intracranial CSF spaces and relative macrocephaly, treatment of hydrocephalus in achondroplasia patients has become relatively uncommon in the last 20 years. Historically, there was a significant association between symptomatic foramen magnum stenosis and treatment of hydrocephalus, although concurrent treatment of both has fallen out of favor with the recognition that CMD alone will treat hydrocephalus in some patients. Despite good experimental data demonstrating that hydrocephalus in achondroplasia is best understood as communicating in nature, ETV appears to be reasonably successful in certain patients and should be considered an option in selected patients.
本研究旨在描述在四个骨骼发育不良中心的 60 年期间,成骨不全症患者中脑积水的发病率和治疗情况。
成骨不全症自然史研究(CLARITY)是一个注册系统,用于从美国四个骨骼发育不良中心接受治疗的成骨不全症患者的临床数据,时间范围为 1957 年至 2017 年。数据输入并存储在 REDCap 数据库中,包括手术适应证和并发症、医学诊断和影像学信息。
本研究共纳入 1374 例成骨不全症患者。其中 123 例(9%)患者在中位年龄 14.4 个月时接受了脑积水治疗。尽管在最近十年中,所有中心的治疗比例均低于 6%,平均每个中心为 2.9%,但各中心治疗脑积水的患者比例存在较大差异,范围为 0%至 28%,并且按出生年份的不同也存在差异。接受颈髓减压术(CMD)是治疗脑积水的强烈预测因素(比值比 5.8,95%置信区间 3.9-8.4),但这种关联在 2010 年以后出生的患者中已经消失(比值比 1.1,95%置信区间 0.2-5.7)。在 1990 年后出生的患者中,内镜第三脑室造瘘术(ETV)治疗脑积水的比例逐渐增高,在最近十年中,38%的患者将其作为一线治疗方法。生存分析表明,大约一半接受 ETV 治疗的患者可以单次治愈脑积水。
虽然许多成骨不全症患儿的颅内脑脊液空间扩大和相对大头与脑积水的特征一致,但在过去 20 年中,成骨不全症患者的脑积水治疗已变得相对少见。从历史上看,症状性枕骨大孔狭窄与脑积水治疗之间存在显著关联,尽管由于认识到 CMD 本身可在某些患者中治疗脑积水,因此同时治疗两者的做法已不再流行。尽管有很好的实验数据表明成骨不全症中的脑积水最好理解为交通性脑积水,但 ETV 在某些患者中似乎效果良好,并且应该作为某些患者的选择之一。